370 related articles for article (PubMed ID: 28440428)
1. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
Kawamura D; Takemoto Y; Nishimoto A; Ueno K; Hosoyama T; Shirasawa B; Tanaka T; Kugimiya N; Harada E; Hamano K
Oncol Rep; 2017 Nov; 38(5):3238-3244. PubMed ID: 29048622
[TBL] [Abstract][Full Text] [Related]
3. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Liang M; Zhao T; Ma L; Guo Y
Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
[TBL] [Abstract][Full Text] [Related]
4. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
Dunlop CR; Wallez Y; Johnson TI; Bernaldo de Quirós Fernández S; Durant ST; Cadogan EB; Lau A; Richards FM; Jodrell DI
Br J Cancer; 2020 Oct; 123(9):1424-1436. PubMed ID: 32741974
[TBL] [Abstract][Full Text] [Related]
5. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Ding L; Madamsetty VS; Kiers S; Alekhina O; Ugolkov A; Dube J; Zhang Y; Zhang JS; Wang E; Dutta SK; Schmitt DM; Giles FJ; Kozikowski AP; Mazar AP; Mukhopadhyay D; Billadeau DD
Clin Cancer Res; 2019 Nov; 25(21):6452-6462. PubMed ID: 31533931
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
7. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
[TBL] [Abstract][Full Text] [Related]
8. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
[TBL] [Abstract][Full Text] [Related]
9. Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.
Mitsuno M; Kitajima Y; Ohtaka K; Kai K; Hashiguchi K; Nakamura J; Hiraki M; Noshiro H; Miyazaki K
Int J Oncol; 2010 Feb; 36(2):341-9. PubMed ID: 20043067
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
11. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
[TBL] [Abstract][Full Text] [Related]
12. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Prevo R; Fokas E; Reaper PM; Charlton PA; Pollard JR; McKenna WG; Muschel RJ; Brunner TB
Cancer Biol Ther; 2012 Sep; 13(11):1072-81. PubMed ID: 22825331
[TBL] [Abstract][Full Text] [Related]
13. Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression.
Wang C; Zhang W; Fu M; Yang A; Huang H; Xie J
Oncol Rep; 2015 Jan; 33(1):383-90. PubMed ID: 25394408
[TBL] [Abstract][Full Text] [Related]
14. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
15. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
[TBL] [Abstract][Full Text] [Related]
16. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
17. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
[TBL] [Abstract][Full Text] [Related]
18. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Morimoto Y; Takeuchi O; Takizawa A; Yoneyama H; Asanuma F; Suzuki Y; Atsuda K; Yamada Y
Anticancer Drugs; 2012 Jun; 23(5):505-14. PubMed ID: 22334000
[TBL] [Abstract][Full Text] [Related]
19. CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer.
Zhou Y; Zheng M; Liu Z; Yang H; Zhu P; Jiang JL; Tang J; Chen ZN
Biochem Biophys Res Commun; 2020 Jul; 528(1):62-70. PubMed ID: 32456796
[TBL] [Abstract][Full Text] [Related]
20. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
Donadelli M; Costanzo C; Beghelli S; Scupoli MT; Dandrea M; Bonora A; Piacentini P; Budillon A; Caraglia M; Scarpa A; Palmieri M
Biochim Biophys Acta; 2007 Jul; 1773(7):1095-106. PubMed ID: 17555830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
